Buclizine
Top View
- Council of Europe Committee of Ministers (Partial
- (12) United States Patent (10) Patent No.: US 8,314,077 B2 Webb Et Al
- Antihistamines and Their Role in Dermatology
- Patients with Dementia and Receiving Tricyclic Antidepressants Or Anticholinergic Agents
- (Therapeutic Products) Regulations 2015
- Chemical Structure-Related Drug-Like Criteria of Global Approved Drugs
- Antihistamines
- Use of Combinations Comprising a Corticosteroid and a Pyrimidopyrimidine in the Treatment of Inflammatory Diseases
- Photosensitizing Drugs
- NVA237 / Glycopyrronium Bromide Multinational, Multi-Database Cohort
- Pharmaceutical Appendix to the Tariff Schedule 2
- Management of Drug Overdose and Poisoning
- Interaction of Antihistaminic Drugs with Human Translationally Controlled Tumor Protein (TCTP) As Novel Approach for Differentiation Therapy
- Toxicology Brief” Was Contributed by Lisa Murphy, VMD, ASPCA Animal Poison Control Center, 1717 S
- Migraleve (Buclizine Hydrochloride, Paracetamol, Codeine Phosphate) Product Information
- Attachment 2
- Migraleve Pink
- Rapid Determination of Ziprasidone and Buclizine Hydrochloride in Pharmaceutical Formulations (Tablets) by Simple Spectrophotometric Method